South China Financial (00619.HK) Hot Stock Analysis Report

As a hot stock in the Hong Kong stock market, the core reason for South China Financial (00619.HK) to attract attention is its strategic layout to enter the AI pharmaceutical field [1]. On November 16, 2025, the company announced that it had signed a memorandum of understanding with an independent third party to establish a joint venture to carry out four major business directions: AI drug research and development platform and technical services, AI drug efficacy prediction platform serving global beauty customers, disease and aging pipeline path development, and direct sales of anti-aging products [1]. The news came at a time when the global popularity of the AI+ healthcare sector is rising, and the market has high expectations for the application prospects of AI technology in drug research and development, anti-aging and other fields, which has promoted investors to pay attention to South China Financial’s transformation actions.

In terms of price and trading volume, the intraday price on December 2, 2025 was HK$0.380, a decrease of 3.80% from the previous trading day, but overall it still maintained a strong medium-to-long-term growth trend — a 75.93% increase year-to-date and a 123.53% increase over one year, significantly outperforming the Hang Seng Index’s 30.56% and 33.97% increases in the same period [1]. The 52-week price range is HK$0.147 - HK$0.475, and the current price is in the upper middle part of the range [1]. In terms of trading volume, the intraday data for the day has not been fully released yet. The historical average trading volume is 493,974 shares, and the trading volume on November 28 was only 12,000 shares, which is significantly lower than the average [1].

• The popularity of South China Financial reflects the market’s high attention to the AI+ healthcare sector, and the company’s transformation layout has become the core driver of stock price growth.
• Although the stock price fell slightly recently (a 3.80% drop on December 2, 2025), the medium-to-long-term performance of outperforming the Hang Seng Index indicates investors’ recognition of the company’s transformation logic, and the short-term fluctuation may be due to profit-taking.
• The company is transforming from the financial services/capital market sector to the AI pharmaceutical field, with a large business span, so attention should be paid to challenges in technology, talent and other aspects.

• Risk Points
  : The company lost HK$295 million in the whole year of 2024 and did not pay dividends, and the continuous loss status constitutes profit pressure [1]; the AI pharmaceutical joint venture is only in the memorandum of understanding stage, with no specific implementation plan and income expectation, so there is uncertainty in business transformation; key valuation indicators such as price-earnings ratio have not been disclosed, and the valuation lacks a clear anchor [1]; the AI pharmaceutical field is highly competitive, and the company needs to face various challenges.
• Opportunity Window
  : The high-growth attribute of the AI+ healthcare sector provides development space for the company’s transformation. If it can successfully promote related businesses, it may bring new profit growth points for the company.

South China Financial (00619.HK) has become a hot stock in Hong Kong due to its entry into the AI pharmaceutical field, with strong medium-to-long-term stock price performance, significantly outperforming the Hang Seng Index. The core catalyst is that the company plans to establish a joint venture to carry out four major business directions including AI drug research and development. Investors need to pay attention to issues such as the company’s continuous losses, uncertainty in business transformation, and valuation risks, and at the same time, they can pay attention to the opportunities brought by the development of the AI+ healthcare sector to the company.